NCT05941507 2025-09-24
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2 Recruiting
LigaChem Biosciences, Inc.
Intensity Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute